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Abstract
Background Fulminant hepatic failure (FHF) is a devastating syndrome, which sometimes results in death or liver
transplantation, in which inflammation would aggravate the
development of fetuin-A which would act as an antiinflammatory factor and may be an available approach to
attenuate FHF.
Aims The purpose of this study was to investigate the
effects of fetuin-A on D-galactosamine/lipopolysaccharide
(D-GalN/LPS)-induced liver failure in mice.
Methods A mouse model of FHF induced by D-GalN/LPS
was established and fetuin-A was injected intraperitoneally
prior to D-GalN/LPS treatment. At different time points
after D-GalN/LPS intervention, serum TNF-a and IL-6
levels were measured by ELISA. Fetuin-A mRNA and
protein expression in liver tissues was assessed by RTPCR, Western blotting and immunohistochemical staining.
Besides, an observation of liver tissue injury, the apoptosis
of hepatocytes, was analyzed by TUNEL assay.

Results Expression of fetuin-A mRNA and protein in
liver tissue were significantly and gradually decreased after
D-GalN/LPS administration. A pre-intervention of exogenous fetuin-A significantly improved the liver function,
decreased TNF-a and IL-6 expression in peripheral blood,
and liver tissue inhibited hepatocyte apoptosis responded to
D-GalN/LPS induction so as to decrease the mortality rates
of FHF mouse. Meanwhile, fetuin-A was negatively correlated with the hepatic pathological score and TNF-a
protein staining in FHF mouse.
Conclusions An intraperitoneal injection of fetuin-A
attenuates D-GalN/LPS-induced FHF in mice. Fetuin-A
might be a protective agent of liver damage partly through
inhibiting liver inflammatory response and hepatocyte
apoptosis.
Keywords Liver failure  Fetuin-A  TNF-a 
Lipopolysaccharide  Endotoximia
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Fulminant hepatic failure (FHF) is a condition with rapid
deterioration of hepatocyte function resulting in hepatic
encephalopathy and/or coagulopathy in the patients [1].
This is a devastating syndrome, which results in death or
the need for liver transplantation in over 50 % of the cases
[2]. Urgent liver transplantation has become the standard
care for most FHF patients in some countries where FHF
survival rates have shown progressive and substantial
improvement with 1-year survival exceeding 80 % [2, 3].
However, in some other countries, access to liver transplantation and other extracorporeal liver-assist devices is
severely limited. On the other hand, FHF also has a positive reversible potential, where survivors recover
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completely without any sequelae. Accordingly, if the
individual can be supported properly throughout the acute
event, recovery will follow the rapid regeneration of
hepatocytes. Thus, it is of important clinical significance to
find a more effective approach to treat patients with FHF
when a liver transplantation is not available.
The mechanisms of FHF are quite complex and still not
fully defined. It is generally acknowledged that immunologic injury, hypoxic ischemic lesion and endotoxemia are
the three main causes. Normally, the transition from stable
cirrhosis to FHF is caused by systemic inflammatory
response, characterized by a predominantly proinflammatory cytokine profile [4]. Therefore, removal of proinflammatory cytokines such as TNF-a in plasma might be
beneficial to FHF patients.
Fetuin-A (formerly named as a2-Heremans-Schmid glycoprotein, AHSG) is an abundant serum protein that is
exclusively produced by the liver, tongue and placenta [5, 6].
As a glycoprotein, fetuin-A carries two N-linked and three
O-linked oligosaccharide chains that terminate with sialic
acid residues and can bind biogenic cationic ions (e.g., Ca2?)
and other anti-inflammatory molecules (e.g., spermine) [7, 8].
Accordingly, fetuin-A has been proposed as an endogenous
inhibitor of pathological mineralization or calcification [9–
12] and an opsonin of cationic molecules (such as spermine)
[7]. During FHF, it was found that liver would orchestrate a
defensive response to inflammation by altering the synthesis
and release of ‘‘acute phase proteins’’ (APPs), such as fetuinA [13]. Data showed that circulating fetuin-A level decreased
significantly (about 30–50 %) during the acute phase of
inflammation and injury [7], while some classic proinflammatory cytokines such as TNF-a, IL-1, and IL-6 increased
[14]. Moreover, higher concentrations of fetuin-A would act
as an anti-inflammatory factor, inhibiting bacterial endotoxin-induced production of proinflammatory mediators
(such as TNF, IL-1, and nitric oxide) in macrophage cultures
effectively implying that fetuin-A is associated with inflammation activity [15]. In an animal model of arrageenaninduced paw edema, intraperitoneal administration of fetuinA attenuated local TNF production and inflammation [16]. In
early cerebral ischemic injury, fetuin-A played a protective
role partly by attenuating the brain inflammatory response
[17]. Therefore, fetuin-A may be an available approach to
control serious inflammation response in FHF. To verify our
hypothesis, we established a mouse model of FHF to explore
roles of fetuin-A in the pathogenesis of FHF.
D-GalN is a commonly used hepatotoxic drug in the FHF
model that induces dose-dependent liver injury while LPS
play an important role in liver injury, and the mechanism is
as follows: (1) Through inflammatory factors, LPS can
damage the completeness of the vascular endothelial cell
and results in microvascular damage, formation of microthrombus and leads to intrahepatic hemorrhage and
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hepatocyte necrosis. (2) LPS promotes secretions of multiple pro-inflammatory cytokines by Hepatic stellat cells,
e.g. TNF-a, IL-1b and IL-6 etc. Combination of D-GalN
and LPS created a better simulation of FHF and has been
widely used recently. In our previous work, we established
a stable and effective mouse model of fulminant hepatic
failure (FHF) induced by D-GalN (600 mg/kg), and LPS
(0.5 mg/kg) through factorial experiment [18–20].

Methods
Animal Studies
Eight-week-old BALB/c mice (SPF, female, 28–30 g) were
obtained from the Hunan Agro-Techniques University
Laboratories (Changsha, China). To induce acute liver failure, the mice (except for the controls) were injected intraperitoneally (i.p.) with D-GalN (600 mg/kg, Department of
Biomedical Engineering, Chongqing Medical College,
China) and LPS (0.5 mg/kg; Escherichia coli, Sigma, St.
Louis, MO) dissolved in phosphate-buffered saline (PBS).
Fetuin-A (100 mg/kg body weight, ICN, Sigma) was injected intraperitoneally 1 h prior to D-GalN/LPS treatment.
The mice were then randomly assigned into five groups
(n = 6 for each): Blank control: no intervention; FHF
group: 600 mg/kg D-GalN with 0.5 mg/kg LPS, i.p.; Sham
group: physiologic saline with 600 mg/kg D-GalN and
0.5 mg/kg LPS, i.p.; Fetuin-A protection group: 100 mg/kg
fetuin-A with 600 mg/kg D-GalN and 0.5 mg/kg LPS, i.p.;
Anti-fetuin-A group: 100 mg/kg rabbit-anti-mouse fetuinA with 600 mg/kg D-GalN and 0.5 mg/kg LPS, i.p.
For continuous stimulation in vivo, BALB/c mice were
maintained under 12-h light/dark cycles with a regular diet
of LPS (0.5 mg/g body weight), D-GalN or bovine serum
albumin (100 mg/g body weight), intraperitoneal bolus of
bovine fetuin-A (100 mg/kg body weight), rabbit antimouse fetuin-A and comparable amount of sterile saline
respectively (except for blank control groups).
At selected time points of the 3rd, 6th and 9th hour after
D-GalN/LPS treatment, the mice were anesthetized and
blood samples were collected and the animals were sacrificed. The liver tissues were harvested by resections and
were either stored in liquid nitrogen for RT-PCR and
Western blot or fixed in 10 % formaldehyde for immunohistochemistry and TUNEL analysis. The mortality rate of
the mice was observed 24 h after the experiment began in
another parallel experiment group. Furthermore, to observe
the potential toxicity and side effects of fetuin-A in cardiac,
renal and hepatic tissue, fetuin-A (100 mg/Kg) was injected intraperitoneally in normal mouse (n = 6), the animals
were sacrificed and the tissues of liver, heart and kidney
were harvested by resections after 24 h. The pathological
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changes were observed in a general way. The Animal Use
Committee of Xiangya Hospital approved all protocols for
treating animals and all mice were treated humanely during
the whole study period.
RT-PCR
For quantification of fetuin-A mRNA expression in mouse
liver tissue, total RNA was isolated and the first strand cDNA
was synthesized by the Advantage RT-for-PCR kit (BD
Biosciences, Palo Alto, CA). The primers for mouse fetuin-A
(GenBank Accession No.: BC012678) as: 50 -TCGGAGTGG
TGTATGAGATGGAAG-30 (sense) and 50 -GGCAGTGTT
GACGGTGTGGAC-30 (antisense) were synthesized by
Boya Company (Shanghai, China). The regular PCR producing a 281 bp fragment was carried out and glyceraldehydes 3-phosphate dehydrogenate (GAPDH, GenBank
Accession No.: BC029618) was used as an internal control.
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labeling (TUNEL, red fluorescence) kit (Doctor Biotechnology, Wuhan, China). Images were observed on a Nikon
Eclipse E800 fluorescent microscope. The average number
of apoptotic cells per high-power field (2009 magnification) was calculated in ten random visual fields for each
sample and six samples for each time point, and the
apoptotic index (AI) of each specimen was scored.
Liver Function Tests and Cytokine Quantification
The serum concentrations of TNF-a and IL-6 in mice were
measured by commercial enzyme-linked immunosorbent
assays (ELISA, Bio Vendor Laboratory Medicine, Brno,
Czech Republic). The level of alanine aminotransferase
(ALT) in mice serum was determined using an automatic
biochemical analyzer (HITACHI-7170A, Hitachinaka City,
Japan).

Western Blotting

Statistical Analysis

Mouse fetuin-A-specific antibodies were obtained from Dr.
Haichao Wang (USA). Goat anti-rabbit aquaporin-2 antibodies were obtained from Santa Cruz (Santa Cruz, CA).
After SDS-PAGE, the proteins were transferred onto PVDF
membrane and hybridized with specific primary antibodies,
and subsequently were incubated with HRP-conjugated
sheep anti-mouse IgG. Bands were visualized using the
ECL kit (Amersham, Piscataway, NJ) per the manufacturer’s instruction [21, 22].

The continuous data were presented as mean ± SD. Using
SPSS 15.0 software (SPSS, Chicago, IL), one-way
ANOVA tests were employed for comparison among all
groups, and Student–Newman–Keuls test was subsequently
applied to compare the statistical difference between two
groups. Meanwhile, multivariate linear regression analysis
was performed using log-transformed data and Pearson’s
correlation coefficient to test the correlation between the
relevant covariates (such as pathological score, grey scales
of TNF-a and fetuin-A, and apoptotic index). All tests were
two-sided and p value \0.05 was considered to be statistically significant.

Histological Assessment and Immunohistochemical
(IHC) Staining
Four lm-thick formalin-fixed liver tissue sections were
incubated with the primary antibody, subsequently incubated
with the secondary antibody conjugated with streptavidin–
biotin–peroxidase complex (Zhongshan Goldenbridge Biotechnology, Beijing, China) and a color reaction was developed using 3,3-diaminobenzidine tetrahydrochloride
(Sigma). The negative control slides were probed with normal rabbit serum under the same experimental conditions.
The histological characteristics of liver tissues were
scored by Ishak Classification [23]. In each case, the
immunoreactivity was determined in five random fields and
the IHC scoring was made independently by two experienced pathologists. The images were analyzed using Image
J, a digital image processing system.
TUNEL Assays
Apoptosis of hepatocytes was detected using terminal
deoxynucleotidyl transferasemediated dUTP nick-end

Results
Liver Injury, Inflammation, and Hepatocyte Apoptosis
in FHF Mouse
At the third hour after D-GalN/LPS administration, the
mice in the FHF group exhibited slightly disordered liver
structure, active blood sinusoid response, ballooning
degeneration of hepatocytes, spot necrosis around the
central veins of the hepatic lobules, scattered inflammatory
cell infiltration, and eosinophilic bodies. After 6 h, the liver
tissues showed aggravated structural disorder, active blood
sinusoid response, lamellar necrosis, eosinophilic hepatocytes, moderate to severe inflammatory cell infiltration and
numerous apoptotic bodies. After 9 h, the tissue showed
widespread necrosis, abundant erythrocyte obturation, piles
of inflammatory cell infiltration, numerous apoptotic bodies and eosinophilic bodies (Fig. 1a). The Ishak score
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Fig. 1 Hepatic injury, TNF-a expression, and apoptosis assessment
in the liver tissues of FHF mouse. a Pathological characteristics of the
hepatic tissues in the FHF mouse model at different time points after
D-GalN/LPS induction (9400). The hepatic injury, such as necrosis,
structural modification, and inflammatory response, was aggravated in
a time-dependent manner. b Immunohistochemistry (IHC) staining of

TNF-a in hepatic tissues at the 0, third, sixth, and ninth hours after
induction in the FHF mouse (9400). Highly concentrated staining of TNF-a in brown color was obvious both in the
hepatocyte cytoplasm and on the cell membrane during the ninth
hour. c Apoptosis of hepatocytes in FHF mouse (9400): the stained
apoptotic cells were indicated with arrowheads

Table 1 The Ishake scores of liver tissue at different time points
after injection of D-GalN/LPS in the FHF group

apoptotic index of hepatocytes was observed in the sixth
hour in the FHF mouse model (Figs. 1c, 3e).

Time point
0h

Mean value
0.000

Standard error (SE)
0.000

3rd hour
6th hour

5.833
9.833

0.654
0.654

9th hour

17.333

0.333

showed that the injury in liver tissue aggravated over time
(Table 1). The IHC staining of TNF-a staining in liver
tissue reached a maximum at the ninth hour after D-GalN/
LPS injection in the FHF group (Fig. 1b). The peak of
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D-GalN/LPS

Fetuin-A Expression in Liver Tissue was Reduced by
Induction in FHF Mouse

D-GalN/LPS

In FHF mouse model, both mRNA and protein expression
(Fig. 2a, b) of fetuin-A in liver tissue were decreased significantly and gradually from the sixth to the ninth hour
after D-GalN/LPS administration. Meanwhile, the significantly decreased fetuin-A protein expression, which was
induced by D-GalN/LPS, was further identified by IHC
staining in the FHF group (Fig. 2c).

Dig Dis Sci (2014) 59:1789–1797
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Fig. 2 Expression of fetuin-A mRNA and protein in D-GalN/LPSinduced FHF mouse. a, b mRNA and protein expression of fetuin-A
in the liver tissues was distinctly decreased in a time-dependent
manner after D-GalN/LPS induction. c, d IHC scores of fetuin-A

staining, which was located in hepatocyte cytoplasm and on cell
membrane of FHF mouse, were significantly decreased in a timedependent manner after D-GalN/LPS induction

Exogenous Fetuin-A Decreased the Mortality of FHF
Mouse Caused by D-GalN/LPS Injection

significantly higher than that in the groups of blank (1,055.21 ±
84.68 nkat/L) (p \ 0.0001, p \ 0.0001, p \ 0.0001, respectively) and fetuin-A protection (31,585.15 ± 4,086.35 nkat/L)
(p \ 0.0001,
p \ 0.0001,
p \ 0.0001,
respectively)
(Fig. 3b).

At the 24th hour of D-GalN/LPS treatment, 83 % (5/6) of
the mice in the FHF group and 100 % (6/6) of the mice in
the groups of sham and anti-fetuin-A were dead. In contrast, only 16.7 % (1/6) of the mice in the fetuin-A protection group died. The administration of fetuin-A has
significantly decreased the mortality rates of the mouse
with FHF induced by D-GalN/LPS (Fig. 3a).
Fetuin-A Improved Liver Function in FHF Mouse
Following D-GalN/LPS injection, the serum ALT significantly increased in a time-dependent manner in FHF mice
(data not shown). At the ninth hour after D-GalN/LPS induction, serum ALT levels in groups of FHF (291,370.76 ±
29,241.68 nkat/L), sham (265,975.30 ± 26,652.21 nkat/L)
and anti-fetuin-A (301,256.25 ± 6,258.38 nkat/L) were

Fetuin-A Attenuated Hepatic Inflammatory Response
to D-GalN/LPS Intervention in FHF Mouse
The peak of serum proinflammatory factors was observed 3 h
after D-GalN/LPS injection. As shown in Fig. 3c, serum TNFa in fetuin-A protection group (233.87 ± 48.03 pg/mL) was
significantly lower than that in both groups of FHF (515.48 ±
46.31 pg/mL, p = 0.034), sham (545.39 ± 62.14 pg/mL,
p = 0.001), and anti-fetuin-A (692.39 ± 310.59 pg/mL, p \
0.0001) groups. Compared with blank control (9.36 ± 6.28
pg/mL), serum TNF-a level in the anti-fetuin-A group with an
antagonism against endogenous fetuin-A in mouse liver was
significantly higher (p \ 0.0001, respectively).
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Fig. 3 Effects of fetuin-A on proinflammatory factors, apoptosis, and
liver function in FHF mouse. a Fatality rate in different experimental
groups after 24 h of induction. b Serum concentration of ALT in
different experimental groups. c Serum concentration of proinflammatory factors of TNF-a and IL-6 in different experimental groups.

d Relative IHC scores of fetuin-A in the liver tissues of different
groups. e Relative IHC scores of TNF-a in the liver tissues of
different groups. f Apoptosis index (AI) of hepatocytes after D-GalN/
LPS intervention in different groups

Meanwhile, the serum level of IL-6 in the fetuin-A
protection group (546.73 ± 56.42 pg/mL) was significantly lower than that in both the FHF (1,093.93 ±
153.15 pg/mL, p \ 0.0001), sham (1,189.26.93 ± 134.72
pg/mL, p \ 0.0001) and anti-fetuin-A groups (1,034.61 ±
266.12 pg/mL, p \ 0.0001), indicating that an intervention
of fetuin-A significantly decreased the serum level of IL-6
in the mouse with FHF. Similar to serum TNF-a comparison, an antagonism against endogenous fetuin-A of mouse
liver in the anti-fetuin-A group significantly increased
serum IL-6 levels compared with blank control (56.87 ±
34.98 pg/mL, p \ 0.0001, respectively) (Fig. 3c). Thus, an
administration of fetuin-A significantly decreased the

serum concentrations of proinflammation factors, such as
IL-6 and TNF-a in the mouse with FHF.
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Fetuin-A and TNF-a Protein Expression in the Liver
Tissues of FHF Mouse
Since D-GalN/LPS intervention inhibited fetuin-A expression in a time-dependent manner and reached the lowest
level at the ninth hour in the liver tissue of FHF mouse
(Fig. 2), the ninth hour was subsequently chosen as the
check point to compare fetuin-A and TNF-a expression
levels among different experimental groups (n = 6). As
shown in Fig. 3d, the relative IHC scores of fetuin-A in the
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Fig. 4 Histological examination of hepatic, renal, and cardiac tissues after fetuin-A injection. 24 h after fetuin-A treatment at the dose of
100 mg/kg, no obvious tissue damage was observed in mouse liver, kidney, and heart (magnification 9200, 9400)

groups of the blank control (114.68 ± 0.67,) and fetuin-A
protection (113.29 ± 1.98) were significantly higher than
that in the groups of FHF (110.89 ± 0.86, p \ 0.0001,
p \ 0.0001,
respectively),
sham
(110.45 ± 0.67,
p \ 0.0001, p \ 0.0001, respectively) and anti-fetuin-A
(109.77 ± 1.01, p \ 0.0001, p \ 0.0001, respectively)
groups.
After D-GalN/LPS injection in mouse, IHC staining of
TNF-a in the liver tissue of FHF mouse was gradually
increased and reached the highest level at the sixth hour.
The relative IHC staining intensities of TNF-a in the
groups of the blank control (112.14 ± 3.07) and fetuin-A
protection (111.95 ± 2.59) were significantly lower than
that in the groups of both FHF (117.01 ± 3.42, p = 0.002,
p \ 0.0001
respectively),
sham
(116.45 ± 2.60,
p = 0.002, p \ 0.0001 respectively) and anti-fetuin-A
(115.55 ± 0.85, p = 0.016, p = 0.0004, respectively)
(Fig. 3e). An intraperitoneal injection prior to D-GalN/LPS
treatment effectively attenuates TNF-a expression in the
liver tissues of the FHF mouse. Moreover, TNF-a expression in the anti-fetuin-A group was significantly higher
than that in the fetuin-A protection group, indicating that
an antagonism against endogenous fetuin-A promoted liver
inflammation in FHF mouse.
Fetuin-A Inhibited the Apoptosis of Hepatocytes
in FHF Mouse
After D-GalN/LPS injection, an obvious hepatocyte apoptosis was observed in the liver tissue of FHF mouse
(Fig. 2f). Apoptosis was found occasionally in the blank

control (0.10 ± 0.32) group. However, the hepatocyte
apoptosis index (AI) in the groups of FHF (23.10 ± 7.39,
p \ 0.0001), anti-fetuin-A (13.50 ± 3.47, p \ 0.0001) and
fetuin-A protection (2.20 ± 2.97) was statistically significant (Fig. 3f). Thus, the interference of fetuin-A significantly inhibited hepatocyte apoptosis induced by D-GalN/
LPS treatment in FHF mouse.
Toxicity and Side Effects of Fetuin-A on Normal
Mouse Liver, Kidney and Heart
As a potential therapeutic drug for FHF, fetuin-A at the
experimental dosage was further evaluated in terms of
potential toxicity and side effects in cardiac, renal and
hepatic tissues. As shown in Fig. 4, all the histological
appearances of cardiac, renal and hepatic tissues were
normal after fetuin-A injection at 100 mg/kg for 24 h
(Fig. 4).
Correlation Among Hepatic Pathological Scores,
Expression of Fetuin-A, TNF-a, and Hepatocyte
Apoptosis
For a multiple linear regression analysis, the hepatic
pathological scores of FHF mouse were adopted as the
dependent variable (Y), while the relative IHC staining
scores of fetuin-A and TNF-a and hepatic AI were
respectively used as the independent variables X1, X2, X3;
a regression equation was constructed as: Y = -4.388 2.682 X1 ? 0.073 X2 ? 0.032 X3 (R2 = 0.603; F test:
F = 7.075, p = 0.004).
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Table 2 Correlation test among pathology score, immunohistochemistry relative gradation value of TNF-a, immunoblotting value of fetuin-A,
and apoptotic index
Variables

Immunoblotting
value of fetuin-A

Immunohistochemistry relative
gradation value of TNF-a

Apoptotic
index

Pathology score

-0.608a

0.595a

0.354

Immunoblotting value of fetuin-A

–

-0.484b

0.144

Immunohistochemistry relative gradation value of TNF-a

–

–

0.269

a

p \ 0.01;

b

p \ 0.05

Moreover, a correlation test was carried out among these
four aforementioned indices. The Pearson’s contiguous
coefficients showed that the relative IHC score of fetuin-A
was negatively correlated with the pathological score,
while the relative IHC score of TNF-a was positively
correlated with the pathological score and the relative IHC
scores of fetuin-A and TNF-a were negatively correlated
with each other (Table 2).

Discussion
In response to infection or injury, the liver re-prioritizes the
synthesis and systemic release of many APPs, one of which
is fetuin-A [24, 25]. In the present study, we found that
fetuin-A expression in liver tissue was time-dependently
decreased during FHF. Meanwhile, fetuin-A expression
was negatively correlated with TNF-a in the liver of FHF
mouse. During FHF, the severe necrosis and apoptosis
directly reduced the number of hepatocytes and also
affected the functions of living cells so that fetuin-A produced by hepatocytes was decreased and the hepatic
functions were severely injured. An exogenous injection of
fetuin-A prior to D-GalN/LPS intervention could lower the
circulating levels of TNF-a and IL-6, decrease hepatic
apoptosis, improve liver function and eventually lower the
fatality rate of FHF mice. With regard to the safety of
intraperitoneal injection of fetuin-A, our data did not find
obvious pathological damage to mouse liver, kidney and
heart tissues at the dose of 100 mg/kg. As a result, an
intraperitoneal administration of fetuin-A attenuated DGalN/LPS-induced liver failure in mice.
Although the mortality and serum ALT levels of FHF
mouse were elevated by a certain dose of anti-fetuin-A
(100 mg/kg) to interfere the endogenous fetuin-A, no statistical significance was found between the groups of FHF
and anti-fetuin-A (100 mg/kg). The possible reasons may
be the abundant endogenous fetuin-A in mice (about
500 mg/kg), so that 100 mg/kg of anti-fetuin-A was not
enough for antagonism. Secondly, an extended sample size
might be better for exhibiting the statistical differences
among different experimental groups.
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The hepatic apoptosis was obvious in our FHF mouse
model. When apoptosis occurred in a large amount of hepatocytes, apoptotic cells were not endocytized promptly by
phagocytes. The cellular contents were delivered after these
cells were distended and split, which stimulated neutrophilic
granulocytes to release and recruit inflammatory factors. Then
inflammatory response was generated, aggravated and prolonged. Previous studies have shown that fetuin-A played an
important role in recognition and clearance of apoptotic cells
[26], inhibited the apoptosis of vascular smooth muscle cells
and reduced the cleavage of caspases 3, 8, and 9 into their
active subunits [27]. So fetuin-A could be a protective agent for
tissue injury through apoptosis inhibition. Moreover, we found
that fetuin-A could also decrease hepatic apoptosis indirectly
by depressing TNF-a, which could induce hepatic apoptosis.
On the other hand, fetuin-A was documented to be
critical in phagocytosis [28] and inhibit the inflammatory
response of macrophages after phagocytosis [29]. In our
study, multiple linear regression analysis demonstrated that
fetuin-A, which was correlated with TNF-a closely but
oppositely, was probably a positive regulator of pathological damage of hepatic tissue in FHF mouse. The decreased
fetuin-A in liver tissue ensures a rigorous innate immune
response manifested by excessive accumulation of proinflammatory mediators. Supplementation with exogenous
fetuin-A could tilt the balance towards inhibiting the
release of activated TNF-a and IL-6.
Fetuin-A is an abundant serum protein that is exclusively
produced by the liver, tongue and placenta. It has biological
homology, high affinity and no significant side effects.
Furthermore, administration of fetuin-A confers protection
against fulminant hepatic failure in the FHF mouse model,
and thus calls for need to further explore its therapeutic
potential for the clinical management of acute liver failure.
In summary, the present study demonstrates fetuin-A as
a negative APP in FHF. Fetuin-A exerts an important
protective role against FHF by counter-regulating systemic
accumulation of proinflammatory mediators.
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